UBS Analysts See Cochlear Unlikely to Restore 10% Sales Growth Aim

UBS analysts say Cochlear is increasingly unlikely to reinstate its 10% annual growth aspiration for hearing implant sales. The analysts maintain a neutral rating and cite headwinds from an impending rival launch.